 | PharmaDeals Agreements* 28,000 records* Covers all territories, therapy areas and stages of development* More than 250 new/updated deals per month* Personalised deal alerts straight to your mailbox* Tailored/boolean search facility* Immediate access to finances and SEC filings* Specialist strategic intelligence team catalogue and categorise every deal* Graphic function* Export Function |
|
| PharmaDeals Agreements* 28,000 records* Covers all territories, therapy areas and stages of development* More than 250 new/updated deals per month* Personalised deal alerts straight to your mailbox* Tailored/boolean search facility* Immediate access to finances and SEC filings* Specialist strategic intelligence team catalogue and categorise every deal* Graphic function* Export Function |
|
| PharmaDeals Agreements* Comprises over 28,000 records catalogued and categorised by our team of analysts* Immediate access to deal finacial details, including the associated US SEC filings* Covers all territories, therapy areas and stages of development* More than 250 new/updated deals per month* Personalised deal alerts straight to your mailbox* Graphic function* Tailored/boolean search facility* Export function |
|
 | This newly updated report is a must read for anyone involved in deal making and builds on the excellent reputation achieved from the previous edition of the report. Based on over 15 years' experience of assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making, the report seeks to demystify the subject of royalty rates, answering key questions such as: What royalty rates are used in pharmaceutical agreements? What are the factors that influence royalty rates? How do I calculate and determine royalty rates? How are other organisations setting their royalty rates? With new insight and data, this report will be valuable to past purchasers of the previous edition in addition to new pharmaceutical players, technology transfer staff and VC firms. |
|
| This report provides an overview of the key issues of intellectual property strategy and competition law strategy affecting pharmaceuticals suppliers. Written by Bird & Bird, it sets out the essential issues concerning the intellectual property regime and the application of competition law in the pharmaceuticals sector, and the sector-specific regulatory provisions affecting competition. |
|
 | This covers those essential market changing initiatives which make tomorrow’s drug market different from today’s. Successful deal making has accurate valuation at its heart. Anything that impacts a drugs ability to achieve in the future a fair and profitable market price impacts its value today. The current market is more challenging than ever before. Payer-driven price negotiation for reimbursement, and cost-containment programmes to control prescribing, both challenge the traditional pricing model the industry has used to generate valuable R&D resource to further the search for innovation and better disease control. |
|
 | This publication provides an essential grounding in how to use accepted and reliable methods for valuing pharmaceutical and biotech projects. Whether you are about to negotiate a licensing deal or need to perform a rigorous portfolio review, it is vital that you understand both the value of a project today and how that value can be built over time. |
|
 | This indispensable report allows even the most experienced deal makers to translate theoretical discussions into reality. It provides many answers to key questions arising in deal situations including: > What are the rationales for different deal structures?> What is the most relevant deal type to use in a particular situation?> What are the key issues that must be considered for each deal type?> How do I value these deals?> What do these deals look like in real life? |
|
 | Nanotechnology in Japan is a rapidly growing area with the Japanese government being one of the biggest financial contributors in the world (€691 million FY2004). This specialist report provides in depth information relating to the developments that are occurring within this specialist field. |
|
 | Focusing on partnering in the healthcare industry, this new report provides a practical 'hands on' guide. The report covers key issues ranging from finding a partner and being the partner of choice, through valuation and negotiation to termination of partnerships. Complete with industry anecdotes the report examines: > What partnering is> How to find the right partner> The intricacies of the partnering process> The approach strategy> Successfully managing the alliance> What happens when it all goes wrong |
|
 | Dedicated to the drug delivery sector, this report offers a concise and focused means of assessing and benchmarking drug delivery deal making activity within the past 9 years. It details valuation methodologies and explores effective deal structuring to ensure maximum returns. It is a critical report for all those involved in deal making across both the pharmaceutical and biotechnology sectors. |
|
 | Focusing on the hot topic of influenza, this report offers a topical insight into both the flu virus and the methods being employed to tackle it. From an investigative angle, the report specifically explores the pharmaceutical industry's R&D endeavours in combating the virus, affording a comprehensive insight into key players in the arena. Main areas of focus covered by the report include:> The virus and its history> Key industry insight> An analysis of the market> Summary of influenza-related deals |
|
 | During 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. These reports will be invaluable to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner. |
|
